Checkpoint inhibitor pneumonitis: Short review of literature and case report

Summary Immune checkpoint blockade (ICB) has fundamentally improved the treatment landscape of advanced lung cancer. Improved tolerability and encouraging duration response in selected patients are some advantages ICB over conventional cytotoxic chemotherapies. However, immune-related adverse events (irAEs) possibly affecting multiple organs pose challenges diagnosis management. Checkpoint inhibitor pneumonitis (CIP) is a rare but clinically highly relevant irAE that can significantly impair quality life be potentially threatening. Since its heterogeneity clinical radiographic presentation, challenging. Treatment usually consists discontinuing or delaying administration ICB. If there no sufficient recovery with this measure, steroid therapy indicated. Although majority cases improves therapy, steroid-refractory CIP therapeutic challenge as currently evidence-based standard treatment. We herein present short review literature case report relapsing under